Physician profile
Robert Lee
NPI 1528291267
$2,140.18
in general payments reported to CMS, 2019-2025
16 companies · $593 in 2025
The $593 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.66 · 2020: $64.20 · 2021: $97.93 · 2022: $338 · 2023: $670 · 2024: $335 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $656.85 | 2022-2025 | Dailies Total1, Tryptyr, Clareon |
| Johnson & Johnson Vision Care, INC. | $335.82 | 2020-2023 | Acuvue |
| Abbvie INC. | $211.19 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $177.56 | 2023-2025 | Infuse, Miebo |
| Coopervision INC. | $124.00 | 2023 | Cvi Contact Lens |
| Amgen INC. | $113.90 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $88.28 | 2021-2023 | Cequa, Xelpros |
| Thea Pharma INC. | $83.36 | 2025 | Iyuzeh |
| Rxsight INC | $67.72 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $62.08 | 2023-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $58.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $54.06 | 2021-2023 | |
| Horizon Therapeutics Plc | $42.90 | 2023 | Tepezza |
| Glaukos Corporation | $23.27 | 2024 | Photrexa |
| Biotissue Holdings INC. | $22.78 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $17.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.